Dec 3 (Reuters) - AstraZeneca has signed a deal worth up to $247 million with U.S. firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. (Reporting by Shivani Tanna in Bengaluru; Editing by William Mallard)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,172 GBX | -0.60% | +0.45% | +14.83% |
May. 15 | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
May. 14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,172 GBX | -0.60% | +0.45% | 239B | ||
4.825 USD | -0.10% | -2.33% | 546M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.83% | 239B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B | |
+0.89% | 124B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca ties up with AI biologics company to develop cancer drug - FT